Sandostatin LAR
( DrugBank: - / KEGG DRUG: - )
5 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 67 | Polycystic kidney disease | 1 |
| 77 | Growth hormone secreting pituitary adenoma | 41 |
| 84 | Sarcoidosis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 2 |
| 227 | Osler disease | 1 |
67. Polycystic kidney disease
Clinical trials : 251 / Drugs : 278 - (DrugBank : 69) / Drug target genes : 97 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
77. Growth hormone secreting pituitary adenoma
Clinical trials : 360 / Drugs : 313 - (DrugBank : 26) / Drug target genes : 26 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
84. Sarcoidosis
Clinical trials : 196 / Drugs : 261 - (DrugBank : 78) / Drug target genes : 73 - Drug target pathways : 183
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
193. Prader-Willi syndrome
Clinical trials : 140 / Drugs : 137 - (DrugBank : 26) / Drug target genes : 51 - Drug target pathways : 64
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
227. Osler disease
Clinical trials : 68 / Drugs : 93 - (DrugBank : 22) / Drug target genes : 25 - Drug target pathways : 156
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|